EGFR and glioblastoma: Eguchi et al. [225,226] produced a nanovehicle composed of a TAT fusion protein and a double-stranded RNA-binding domain to efficiently deliver epidermal growth factor receptor (EGFR) and AKT serine/threonine kinase 2 (Akt2) siRNAs to intracranial glioblastoma tumors in a mouse model.